Thomas Russo
Gardner Russo & Quinn
Thomas Russo Abbott Laboratories stake
total: 273
Gardner Russo & Quinn ABT trades
- Total transactions:
- 16
- New positions:
- 1
- Added:
- 5
- Reduced:
- 10
- Held since:
- 2013 Q2 or earlier
- Held for:
- 53+ quarters
- Latest activity:
- 2024 Q2
According to 2026 Q2 report, Thomas Russo holds 11,510 Abbott Laboratories (ABT) shares with a market value of roughly $1.04M accounting for 0.01% of the overall portfolio. Gardner Russo & Quinn has held ABT since at least 2013 Q2 with 86,303 shares in our earliest available record. Since at least 2013 Q2, Gardner Russo & Quinn has made 15 more transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $35.67
- Weighted AVG sell price:
- $44.20
Thomas Russo's historical trades in Abbott Laboratories
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q2
|
0.01%
|
11,510
|
$103.91
|
$1,196,004
|
-0.86% (-100)
|
-0%
|
|
2023 Q2
|
0.01%
|
11,610
|
$109.02
|
$1,265,722
|
-1.40% (-165)
|
-0%
|
|
2022 Q2
|
0.01%
|
11,775
|
$108.62
|
$1,279,000
|
-4.07% (-500)
|
-0%
|
|
2021 Q3
|
0.01%
|
12,275
|
$118.13
|
$1,450,000
|
+2.51% (+300)
|
+0%
|
|
2020 Q3
|
0.01%
|
$108.81
|
+1.40% (+165)
|
|||
|
2020 Q1
|
0.01%
|
$78.92
|
-2.48% (-300)
|
|||
|
2019 Q1
|
0.01%
|
$79.93
|
-13.25% (-1,850)
|
|||
|
2018 Q2
|
0.01%
|
$60.96
|
+9.06% (+1,160)
|
|||
|
2017 Q4
|
0.01%
|
$57.03
|
-22.42% (-3,700)
|
|||
|
2017 Q3
|
0.01%
|
$53.33
|
-0.60% (-100)
|
|||
|
2017 Q2
|
0.01%
|
$48.61
|
+1.22% (+200)
|
|||
|
2016 Q2
|
0.01%
|
$39.33
|
-19.61% (-4,000)
|
|||
|
2016 Q1
|
0.01%
|
$41.81
|
-76.11% (-65,000)
|
|||
|
2014 Q4
|
0.04%
|
$45.02
|
-1.28% (-1,103)
|
|||
|
2013 Q3
|
0.03%
|
$33.19
|
+0.23% (+200)
|
|||
|
2013 Q2
|
0.04%
|
$34.88
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.